Anti-Rheumatic Rx

Biologic Persistence in Psoriatic Arthritis and Psoriasis

Save

Two recent studies examined the durability and persistence of biologic agents in patients with psoriasis (PSO) and psoriatic arthritis (PsA) and while some differences were noted overall persistence was low 3 years later.

Inflammatory Arthritis Spread by ATP and Neural Crosstalk

Save

A novel study from the Journal of Experimental Medicine suggests that a reflex neural signaling at sites of inflammation may lead to spread to other inflammatory sites via and ATP-mediated neural crosstalk. Such findings may be important in disorders like rheumatoid arthritis (RA)

Relevance of Raynaud’s in Systemic Sclerosis

Save

Raynaud’s phenomenon (RP) is integral to the diagnosis and management of systemic sclerosis (SSc) patients; a recent analysis suggests that RP should be characterized based on color change and the presence of other symptoms to know whether RP portends more serious manifestations.

RNL 2022: Spondyloarthritis Spectrum

Save

This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.

- Microbiome in Spondyloathritis - Jose Scher, MD

- Axial Psoriatic Arthritis - Philip Mease, MD

- Juvenile Spondyloathritis - Pamela Weiss, MD

Multimorbidity Burden in Rheumatoid Arthritis

Save

Crowson and colleagues at the Mayo Clinic have shown that rheumatoid arthritis (RA) patients have a higher prevalence of multimorbidity with as many as 44 different morbidities of interest in RA.

This population-based study examined prevalent RA as of January 2015 and sought to

Acute Inflammatory Responses Needed to Resolve Chronic Pain

Save

Science Translational Medicine has published results of a Canadian study of low back pain (LBP) suggests that pain control by anti-inflammatory treatments might have negative effects on pain duration and may be counterproductive for long-term pain outcomes.

Bimekizumab Development Delayed by FDA

Save

UCB announced they have received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis (PSO).

Methotrexate Monitoring (5.13.2022)

Save

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.

1. 
   

   Risk factors for readmission among 132,400 #SLE hospitalizatiions included

Can You Reduce Frequency of Methotrexate Monitoring?

Save

Observational research presented at the British Society for Rheumatology meeting suggest that, based on the COVID-19 pandemic experience, reduced frequency of routine lab monitoring in patients receiving weekly methotrexate therapy for rheumatoid arthritis (RA) was not associated with an

Bimekizumab's Favorable Safety Profile in Psoriasis

Save

A 2-year safety study of bimekizumab, the dual IL-17A/F inhibitor, plaque psoriasis patients showed bimekizumab (BMK), to be effective, well tolerated, with no new safety concerns other than a modest risk of oral candidiasis.

RNL 2022: Psoriatic Arthritis Advances

Save

Tuesday Nite Rheumatology on 10 May 2022 featured session highlights from RheumNow Live 2022.

This webinar presented exerpts from these lectures along with audience Q & A

• Psoriatic Arthritis Guidelines Arthur Kavanaugh, MD


• Drug Targeting in PsA Bruce Kirkham

Making You the Expert of You! (Smart Rules for Patients)

Save

You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.

Polygenic Risk Scores to Identfy Severe Knee and Hip Osteoarthritis

Save

Prevention of knee and hip osteoarthritis would obviate considerable disability and future surgery.  We may be one step closer according to a prospective European GWAS study showing polygenic risk scores (PRSs) significantly associated with higher risks for knee and hip OA joint replacement

Diagnostic Delays in Spondyloarthritis Still Prolonged

Save

Previously quoted average  delay in diagnosing axial spondyloarthritis (axSpA) may be improving as a recent UK study shows the mean average time to diagnosis in two different NHS trusts was between five and six years. 

The diagnostic delay in axSpA has been attributed to a slower

What is JAKne? (5.6.2022)

Save

Dr. Jack Cush reviews the news, journal reports, FDA actions, new side effects and changing prevalence of Gout.

1. 
   

   Gout affects >10 million (4%) in USA, but now w/ more ethnicity, with highest risk in Native Hawaiians (HR 2.21), followed by Black (1.34) and Japanese (1.14);

Lack of Research Stymies Uptake of Medical Marijuana for Rheumatic Pain

Save

A new review article from CreakyJoints finds that there has been limited progress in understanding the potential of cannabis based therapies for the treatment of pain associated with rheumatic conditions in the past five years because of a lack of standardization of clinical research and

Acne with JAK Inhibitors

Save

JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAK inhibitors (JAKi).

BSR Guideline on Idiopathic Inflammatory Myopathy

Save

The British Society of Rheumatology (BSR) has published evidence-based guidelines for idiopathic inflammatory myopathy (IIM) affecting juvenile and adult-onset disease. This rare condition has an estimated prevalence of 5-15 per 100,000 persons.

Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritis

Save

Analysis of rheumatoid arthritis (RA) data from the British Society for Rheumatology Biologics Register shows that, even after failing three or more biologic or targeted synthetic DMARDs (b/tsDMARDs), patients may continue to benefit from repeated trials of unused b/tsDMARDs. 

Trends in Rheumatoid Arthritis Disabililty, Despite Biologics

Save

Disability claims in the U.S. related to rheumatoid arthritis (RA) were just as common in 2015 as in 1999, a government researcher found, against expectations that the advent of biologic therapy would have led to a steady decrease.

Over that 17-year period, rates of Medicare